-
公开(公告)号:EP4457774A1
公开(公告)日:2024-11-06
申请号:EP21859382.0
申请日:2021-12-29
-
公开(公告)号:EP4452494A1
公开(公告)日:2024-10-30
申请号:EP22840287.1
申请日:2022-12-23
发明人: JINDAL, Srijan , KELL, Douglas
-
3.
公开(公告)号:EP4404963A1
公开(公告)日:2024-07-31
申请号:EP22865830.8
申请日:2022-09-02
发明人: MELZER, Emily S. , SANTAMARIA, Carolina , ROBERTS, Eugenia , KOYASSERIL-YEHIYA, Thameez M. , SIEGRIST, M. Sloan
IPC分类号: A61K39/35 , C07K14/195 , C12N1/20 , C12Q1/02 , C12Q1/18 , G01N33/569 , G01N33/53
CPC分类号: C12Q1/18 , C12R2001/44520210501 , C12R2001/1920210501 , C12R2001/3420210501
-
4.
公开(公告)号:EP4402541A1
公开(公告)日:2024-07-24
申请号:EP22870666.9
申请日:2022-09-15
CPC分类号: C12Q1/04 , C12Q1/06 , C12Q1/18 , G01N21/453 , G03H2001/003320130101 , G03H2001/00520130101 , G03H2001/044720130101 , G03H1/0443 , G03H1/06 , G03H2223/1220130101 , G03H1/2645 , G03H2001/26620130101 , G06N3/0464 , G06N3/09 , G01N2015/145420130101 , G01N15/1434 , G01N15/1429 , G01N2015/100620130101 , G01N2015/149320130101 , G01N2015/149720130101 , G01N15/0227 , G01N2015/029420130101 , G06N3/084 , G01N15/1433
-
5.
公开(公告)号:EP4377914A1
公开(公告)日:2024-06-05
申请号:EP22760681.1
申请日:2022-07-29
申请人: Bacteromic Sp.z.o.o.
CPC分类号: G06V20/698 , C12Q1/18 , G06V10/82
-
公开(公告)号:EP4377470A1
公开(公告)日:2024-06-05
申请号:EP22850346.2
申请日:2022-07-29
发明人: PULEO, Christopher Michael , KVAM, Erik Leeming , WONG, Pak Kin , TORAB, Peter , SURRETTE, Christine Lynne
CPC分类号: C12Q1/24 , C12Q1/18 , G01N33/491
-
公开(公告)号:EP4327875A3
公开(公告)日:2024-05-22
申请号:EP23210115.4
申请日:2019-04-25
发明人: WEI, Lai
CPC分类号: C12N1/20 , C12Q1/025 , A61K49/0008 , A61K31/43 , A61K31/7036 , A61K31/4164 , A61K31/65 , G01N33/5088 , G01N2800/1620130101 , G01N2500/1020130101 , A61K35/742 , A61K35/747 , A61K35/744 , A61K2035/11520130101 , Y02A50/30 , C12Q1/18
摘要: Provided herein are screening methods and animal models related to intraocular diseases such as age-related macular degeneration (AMD). For example, provided herein are screening methods for identifying candidate therapeutics for treating or preventing eye diseases, such as AMD. The screening method can be an in vitro screening method or an in vivo screening method, e.g., using an animal model described herein. Animal models are also provided herein, for example, for screening candidate therapeutics for treating or preventing eye diseases, such as AMD. Methods of preparing the animal models are also described herein. Methods of treating or preventing AMD are also provided.
-
公开(公告)号:EP2424559B1
公开(公告)日:2024-04-03
申请号:EP10772493.2
申请日:2010-04-26
-
公开(公告)号:EP4320260A1
公开(公告)日:2024-02-14
申请号:EP22784247.3
申请日:2022-04-05
申请人: Tets, Victor , Tets, Georgy
发明人: Tets, Victor , Tets, Georgy
-
公开(公告)号:EP4306648A2
公开(公告)日:2024-01-17
申请号:EP23195231.8
申请日:2015-05-18
申请人: Regeneron Pharmaceuticals, Inc. , Yale University , Institute for Research in Biomedicine (IRB)
IPC分类号: C12Q1/18
摘要: Genetically modified non-human animals expressing human EPO from the animal genome are provided. Also provided are methods for making non-human animals expressing human EPO from the non-human animal genome, and methods for using non-human animals expressing human EPO from the non-human animal genome. These animals and methods find many uses in the art, including, for example, in modelling human erythropoiesis and erythrocyte function; in modelling human pathogen infection of erythrocytes; in in vivo screens for agents that modulate erythropoiesis and/or erythrocyte function, e.g. in a healthy or a diseased state; in screens for agents that are toxic to erythrocytes or erythrocyte progenitors; in in vivo screens for agents that prevent against, mitigate, or reverse the toxic effects of toxic agents on erythrocytes or erythrocyte progenitors; in in vivo screens of erythrocytes or erythrocyte progenitors from an individual to predict the responsiveness of an individual to a disease therapy.
-
-
-
-
-
-
-
-
-